Molecular engineering of a small trypsin inhibitor based on the binding loop of horsegram seed Bowman-Birk inhibitor

Muricken, Deepa G.; Gowda, Lalitha R.

doi:10.3109/14756366.2010.536158

Cited by 8 publications

(3 citation statements)

References 42 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 Furthermore, BBI has recently been proposed as an oral delivery treatment for multiple sclerosis, 12 and its biotechnological potential as a molecular building block is still being explored. 13,14 Polyclonal, anti-BBI antibodies have been developed, but their apparent affinity against the BBI was too low; therefore, the resulting immunoassays were not sensitive enough to detect BBI in complex samples such as processed foods. 15,16 More recently, a small number of monoclonal antibodies, specific for the native BBI structure, have been used to analyze soy products.…”

Section: ■ Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Probing the Soybean Bowman–Birk Inhibitor Using Recombinant Antibody Fragments

Muzard

Fields

O'Mahony

et al. 2012

J. Agric. Food Chem.

View full text Add to dashboard Cite

The nutritional and health benefits of soy protein have been extensively studied over recent decades. The Bowman-Birk inhibitor (BBI), derived from soybeans, is a double-headed inhibitor of chymotrypsin and trypsin with anticarcinogenic and anti-inflammatory properties, which have been demonstrated in vitro and in vivo. However, the lack of analytical and purification methodologies complicates its potential for further functional and clinical investigations. This paper reports the construction of anti-BBI antibody fragments based on the principle of protein design. Recombinant antibody (scFv and diabody) molecules targeting soybean BBI were produced and characterized in vitro (K(D)~1.10(-9) M), and the antibody-binding site (epitope) was identified as part of the trypsin-specific reactive loop. Finally, an extremely fast purification strategy for BBI from soybean extracts, based on superparamagnetic particles coated with antibody fragments, was developed. To the best of the authors' knowledge, this is the first report on the design and characterization of recombinant anti-BBI antibodies and their potential application in soybean processing.

show abstract

Section: ■ Introductionmentioning

confidence: 99%

“…No major clinical evidence of toxicity has been observed to date . Furthermore, BBI has recently been proposed as an oral delivery treatment for multiple sclerosis, and its biotechnological potential as a molecular building block is still being explored. , …”

Section: Introductionmentioning

confidence: 99%

Probing the Soybean Bowman–Birk Inhibitor Using Recombinant Antibody Fragments

Muzard

Fields

O'Mahony

et al. 2012

J. Agric. Food Chem.

View full text Add to dashboard Cite

show abstract

“…Results indicated that the activity of BBI survived thermal processing, storage and digestion processes. Furthermore, BBI has been proposed as an oral delivery treatment for multiple sclerosis or other autoimmune disorders (Gran et al, 2006;Safavi & Rostami, 2012) and its biotechnological potential as a molecular building block is still being explored (Losso, Munene, Bansode, & Bawadi, 2004;Muricken & Gowda, 2011). Thus, soybean seed coats may provide a new, inexpensive source of BBI concentrate for use as a potential anticancer agent.…”

Section: Bowman Birk Inhibitormentioning

confidence: 99%

Soybean Seed Coats: A Source of Ingredients for Potential Human Health Benefits-A Review of the Literature

O’Bryan¹,

Kushwaha²,

Babu³

et al. 2014

JFR

View full text Add to dashboard Cite

<p>Soybean seed coats are an underutilized byproduct from the commercial crushing of soybeans to make soymeal and soy oil. These seed coats constitute 7 to 10% of the weight of a bushel of soybeans so they provide a substantial opportunity to add value to each bushel. Overall, the United States produces approximately 6 million metric tons of seed coats each year. Biologically active compounds contained in soybean seed coats have been shown to prevent and or reduce macular degeneration, obesity, cancer, and many other debilitating diseases. For example the seed coats of YJ-100 black soybeans contain more than 20 mg/g of anthocyanins, the highest concentration of anthocyanins of all plants materials including other row crops. The purpose of this paper is to examine the chemical content of soybean seed coats, highlight opportunities to add value and discuss the potential health benefits of these chemicals.</p>

show abstract